Diagnostic value of sST2, VCAM-1, and adiponectin in patients with breast cancer to predict anti-tumour treatment-related cardiac events

• Verfasst von: Rosenkaimer, Stephanie L. [VerfasserIn]
• Verfasst von: Winter, Laura [VerfasserIn]
• Verfasst von: Sieburg, Tina [VerfasserIn]
• Verfasst von: Maier, Sandra [VerfasserIn]
• Verfasst von: Mavratzas, Athanasios [VerfasserIn]
• Verfasst von: Hofmann, Wolf-Karsten [VerfasserIn]
• Verfasst von: Akın, Ibrahim [VerfasserIn]
• Verfasst von: Dürschmied, Daniel [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Verfasst von: Hohneck, Anna [VerfasserIn]
• Titel: Diagnostic value of sST2, VCAM-1, and adiponectin in patients with breast cancer to predict anti-tumour treatment-related cardiac events
• Titelzusatz: a pilot study
• Verf.angabe: Stephanie Luise Rosenkaimer, Laura Winter, Tina Sieburg, Sandra Maier, Athanasios Mavratzas, Wolf-Karsten Hofmann, Ibrahim Akin, Daniel Duerschmied, Ralf-Dieter Hofheinz, Anna Hohneck
• E-Jahr: 2022
• Jahr: September 2022
• Umfang: 10 S.
• Fussnoten: Online veröffentlicht: 28. June 2022 ; Gesehen am 30.09.2024
• Titel Quelle: Enthalten in: Oncology research and treatment
• Ort Quelle: Basel : Karger, 2014
• Jahr Quelle: 2022
• Band/Heft Quelle: 45(2022), 10 vom: Sept., Seite 598-607
• ISSN Quelle: 2296-5262
• DOI: doi:10.1159/000525683
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1903732247

Abstract

Aim: The present exploratory study investigated the diagnostic value of inflammatory markers in patients with breast cancer to predict anti-tumour treatment-related cardiac events. Methods: Twenty-one patients with breast cancer were enrolled in this prospective observational study and followed over 6 months. Transthoracic echocardiography and measurement of cardiac (N-terminal prohormone of brain natriuretic peptide (NT-proBNP), troponin I (TnI)) and inflammatory biomarkers (vascular adhesion molecule 1 (VCAM-1), soluble suppression of tumorigenesis-2 (sST2), adiponectin) was performed at 3-month intervals (baseline, follow-up, final visit). Cardiac events were defined as decrease in left ventricular ejection fraction (LVEF, decrease by 10% or <50%) or increase in global longitudinal strain (GLS, increase by 15% or > −16%), as a more sensitive marker of LV function. Results: Cardiac deterioration was observed in 9 out of 21 patients (event group). While LVEF did not differ significantly between the two groups (event vs. no event) at any visit, GLS was significantly higher during follow-up (follow-up: event −16 ± 3.3% vs. no event −18 ± 1.6%, p = 0.04; final visit: event −16 ± 2.1% vs. no event −19 ± 1.9%, p = 0.003). NT-proBNP was numerically higher in patients with a cardiac event during all visits, with NT-proBNP negatively correlated with LVEF and MAPSE (both r = −0.33, p = 0.02), whereas GLS (r = 0.40, p = 0.006), TnI (r = 0.44, p = 0.001), and VCAM-1 (r = 0.48, p = 0.003) showed a positive association with NT-proBNP. In comparison, higher VCAM-1 and sST2 concentrations were detected in the event group at both baseline and the final visit, with a significant difference for baseline (VCAM-1: p = 0.02; sST2: p = 0.03). Adiponectin was also lower in patients with a treatment-related event. Thresholds for VCAM-1 >762 ng/mL and sST2 >18.7 ng/mL, as detected by ROC analysis, correlated best with the primary endpoint. Conclusion: Cardiac events during anti-tumour treatment in patients with breast cancer are relatively common. Inflammatory markers such as VCAM-1 or sST2 were associated with an increased likelihood for occurrence of a treatment-related event, which may therefore hold the promise to better identify patients at high risk.